Navigation Links
Viropharma Comments On Upcoming FDA Advisory Committee Meeting
Date:6/5/2008

EXTON, Pa., June 5 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) notes that FDA has published a notice of a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to be held on July 23, 2008. The Committee will address several issues at this meeting, including a discussion of:

" ... presentations from the Office of Generic Drugs (OGD) on the

bioequivalence methods for locally acting drugs that treat

gastrointestinal (GI) conditions ... "

For over two years, ViroPharma has called for a deliberative public discussion that would include input from clinicians as well as biopharmaceutics and dissolution experts. Bioequivalence determinations for locally acting GI drugs, particularly drugs like Vancocin(R) that treat a serious and potentially life threatening disease, are complex. Clostridium difficile infection results in significant morbidity and mortality, and has developed into a national health issue. The risk to patients of a product that is not bioequivalent to Vancocin in this setting is high.

"While the notice does not specifically identify Vancocin, ViroPharma intends to take every opportunity to ensure the points we've raised through our submissions will be brought forward to this committee," commented Thomas F. Doyle, ViroPharma's vice president, strategic initiatives.

ViroPharma is encouraged that FDA is taking this first step to allow a critique of OGD's bioequivalence proposals. As the company noted in a letter that it sent to FDA earlier this year (newly available on the company's website at http://www.viropharma.com/OGDpetition/), bioequivalence for Vancocin is deser
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
3. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
4. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
5. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
6. ViroPharma to Present at the BIO CEO & Investor Conference
7. ViroPharma Provides 2008 Outlook
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. American Oriental Bioengineering Comments on Earthquake
10. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
11. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... manufacture parts and assemble MOD® units, an innovative medication dispenser produced ... ... February 15, 2009 -- Zeus, Inc., a global leader in the ... new partnership with Avancen MOD Corporation. Avancen produces the MOD ...
... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
... Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) ... the biopharmaceutical industry, it has maintained its focus ... of sustained profitability. The Company was announcing results ... , In a news release today, William J. ...
Cached Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... MAIncreasing nitrogen runoff from urban and agriculture land-use is ... reducing this pollutant before it endangers delicate downstream ecosystems, ... from the MBL (Marine Biological Laboratory) Ecosystems Center. ... issue of Nature, are based on a major study ...
... returning to beaches will face the reality of "red tide" ... swimming and pose risks to humans and sea life. ... running through their neighborhoods play a critical role in filtering ... new study published in this week,s edition of the journal ...
... Healthy streams play a major role in minimizing the ... delivered downstream. This ecosystem service is valuable; excess nitrogen ... and depleting the water of oxygen. This phenomenon, also ... This week, a team of scientists that included ...
Cached Biology News:Increasing nitrogen pollution overwhelms filtering capability of streams 2From the backyard to the ocean: New study shows streams act as key nitrogen filters 2Small streams mitigate human influence on coastal ecosystems 2
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Biology Products: